Provided by Tiger Fintech (Singapore) Pte. Ltd.

Instil Bio, Inc.

38.33
+3.269.28%
Volume:57.01K
Turnover:2.14M
Market Cap:251.41M
PE:-3.20
High:38.87
Open:36.07
Low:35.76
Close:35.07
Loading ...

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

GlobeNewswire
·
11 Apr

TIL Enviro Full Year 2024 Earnings: EPS: HK$0.066 (vs HK$0.073 in FY 2023)

Simply Wall St.
·
29 Mar

Press Release: Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

Dow Jones
·
29 Mar

Till Capital Addresses Tax Reporting Error on Capital Distribution

TIPRANKS
·
29 Mar

Mamata Machinery Ltd. Strengthens Investor Relations and Compliance

TIPRANKS
·
23 Mar

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

GlobeNewswire
·
17 Mar

Instil Bio Price Target Maintained With a $110.00/Share by HC Wainwright & Co.

Dow Jones
·
05 Mar

Instil Bio’s Promising Pipeline and Strategic Collaborations Drive Buy Rating

TIPRANKS
·
05 Mar

JMP Securities Keeps Their Hold Rating on Instil Bio (TIL)

TIPRANKS
·
05 Mar

Instil Bio reports Q4 adjusted EPS ($1.08) vs. ($1.26) last year

TIPRANKS
·
04 Mar

Instil Bio Q4 2024 GAAP EPS $(1.82) Beats $(3.22) Estimate, Instil Had $115.1M In Total Cash, Cash Equivalents, Restricted Cash And Marketable Securities, That Is Expected To Fund Its Current Operating Plan Beyond 2026

Benzinga
·
04 Mar

BRIEF-Instil Bio Q4 Basic EPS USD -1.82

Reuters
·
04 Mar

Instil Bio Q4 Basic EPS USD -1.82

THOMSON REUTERS
·
04 Mar

Instil Bio Inc - Expects Cash to Fund Operations Beyond 2026

THOMSON REUTERS
·
04 Mar

Press Release: Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Dow Jones
·
04 Mar

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024

GlobeNewswire
·
28 Feb

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
22 Feb

My 3 Favorite Stocks to Buy Right Now

Motley Fool
·
20 Feb

Private equity firms who hold 38% of Instil Bio, Inc. (NASDAQ:TIL) gained 34%, institutions profited as well

Simply Wall St.
·
20 Feb

EQT Reports Fourth Quarter and Full Year 2024 Results and Provides 2025 Guidance

PR Newswire
·
19 Feb